Lv4
478 积分 2024-06-19 加入
Prospective, multicentre phase II study to evaluate the clinical benefit of reduced‐dose lenalidomide and dexamethasone based on frailty stratification in elderly, unfit patients with newly diagnosed multiple myeloma
30天前
已完结
A dexamethasone‐free daratumumab–ixazomib regimen in frail elderly patients with relapsed or refractory multiple myeloma: Results of the IFM 2018‐02 phase II study
30天前
已完结
Pembrolizumab and low-dose, single-fraction radiotherapy for patients with relapsed or refractory multiple myeloma: a prospective, single-centre, single-group, open-label, phase 2 pilot trial in the USA
3个月前
已完结
The impact of histone deacetylase inhibitors on immune cells and implications for cancer therapy
3个月前
已完结
Combining Radiation Therapy with Bispecific Antibodies: Outcomes in Relapsed/Refractory Hematologic Malignancies
3个月前
已关闭
Outcomes of Bridging Therapy in Patients With Relapsed/Refractory Large B Cell Lymphoma Receiving Third‐Line CAR T
3个月前
已完结
Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy
3个月前
已完结
Outcomes of patients with R/R B-cell NHL and limited (<5 sites) pre-CART disease bridged with or without radiotherapy
5个月前
已关闭
Don't Put the CART Before the Horse: The Role of Radiation Therapy in Peri-CAR T-cell Therapy for Aggressive B-cell Non-Hodgkin Lymphoma
5个月前
已完结
Role of bridging RT in relapsed/refractory diffuse large B-cell lymphoma undergoing CAR-T therapy: a multicenter study
5个月前
已完结
皖公网安备34019202002308
